The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | Aflibercept plus FOLFIRI in Polish patients with metastatic colorectal cancer
Lucjan Wyrwicz, MD, PhD, Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland, comments on the role of aflibercept, a VEGF inhibitor, with FOLFIRI in patients with metastatic colorectal cancer. Studies have shown the regimen to be effective in Polish patients, and Dr Wyrwicz highlights the need for smaller scale studies in individual countries, where they can provide context to larger, global trials. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
